Teva Licenses U.S. Rights to Infliximab, Etanercept Biosimilars
PharmExec (Pharmaceutical Executive)Topic alignment 90
Filed under
- Biosimilarsmatch 90
Teva and Samsung Bioepis Enter Into Licensing Agreement to Commercialize Etanercept and Infliximab Biosimilars in the U.S.
Big Molecule WatchTopic alignment 85
Keytruda biosimilars are coming — but they face an uphill battle
BioPharma DiveTopic alignment 92
FDA Approves Xbrane’s LUCAMZI™, a Biosimilar to LUCENTIS®
Big Molecule WatchTopic alignment 90
How the Biosimilars Access and Affordability Act Redefines IRA Delays
The Center for BiosimilarsTopic alignment 92